Context Therapeutics Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter report. Context is a clinical-stage biopharmaceutical company focused on female cancers. It completed a corporate reorganization in April 2021 and began trading on Nasdaq as CNTX in October 2021.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $3.8 million | $1.6 million |
| General and administrative expense | $3.6 million | $0.9 million |
| Acquired in-process R&D expense | $3.1 million | None |
| Loss from operations | $10.5 million | $2.6 million |
| Net income (loss) | $(10.5) million | $6.6 million |
| Cash used in operating activities | $8.8 million | $1.0 million |
| Cash and cash equivalents at year-end | $49.6 million | $0.3 million |
| Total assets / total liabilities at year-end | $51.3 million / $3.0 million | $0.5 million / $9.6 million |
The company has no product revenue and has never been profitable. FY2020 net income reflected a $9.9 million noncash gain from changes in the fair value of convertible promissory notes; the notes were converted by 2021. FY2021 expense growth reflected increased clinical and preclinical work, manufacturing, headcount, public-company costs, and the Integral CLDN6 license. No product margins are reported. Year-end liabilities consisted mainly of accounts payable and accrued expenses; the company reported no outstanding convertible notes or note payable at year-end.
Financing activities provided $58.4 million in 2021, including $24.4 million net proceeds from the IPO and $29.0 million net proceeds from a December private placement, as well as Series A proceeds. The private placement included 5.0 million common shares and warrants to purchase 5.0 million shares. Management estimates existing cash will fund operations into 2024, but says the estimate depends on assumptions and additional capital will be needed to advance development.
Material changes and business developments
- R&D expense rose 132% year over year to $3.8 million; G&A expense rose 290% to $3.6 million. Operating loss increased from $2.6 million to $10.5 million.
- Operating cash use increased to $8.8 million from $1.0 million. Cash rose sharply following the IPO and private placement.
- ONA-XR, the lead progesterone-receptor antagonist, was being evaluated in multiple investigator-sponsored trials in breast, ovarian, and endometrial cancers. The filing anticipated preliminary trial results during 2022 and stated that Phase 3 advancement might be considered in 2023, depending on results.
- CLDN6xCD3 bispecific antibody remained preclinical; candidate selection for IND-enabling studies was expected in the second half of 2022.
- Under the Integral license, Context received worldwide bispecific-antibody rights to CLDN6 patents and recorded $3.1 million of acquired in-process R&D expense. Potential payments include up to $55.3 million in development and regulatory milestones, up to $130 million in sales milestones, and royalties up to 12%.
- Tyligand received exclusive ONA-XR development and commercialization rights in China, Hong Kong, and Macau; Context retained rights elsewhere. Context paid an $0.8 million process-development milestone and may owe up to $5.0 million in further manufacturing milestones.
Outlook, risks, and unusual items
- Management expects continued operating losses and higher R&D, G&A, and capital needs for the foreseeable future; no product sales are expected for several years, if at all. The company may seek equity or debt financing, collaborations, or licensing arrangements, which could dilute shareholders or require relinquishing rights.
- Key risks include clinical failure or delays, uncertain safety and efficacy, lengthy regulatory review, dependence on third-party trial and manufacturing providers, competition, intellectual-property challenges, and possible COVID-19-related disruption. Prior onapristone formulations raised liver-safety concerns; the filing describes liver-enzyme events with ONA-XR as a continuing safety consideration.
- Clinical observations cited in the filing are early or from small studies and may not predict later results. The filing cautions that interim and preliminary data can change after verification.
- The December 2021 financing added substantial dilution exposure through warrants. At December 31, 2021, 5.5 million common-stock warrants were outstanding, generally exercisable at $6.25 per share.
- The company reported no material litigation. Its auditor issued an unqualified opinion on the financial statements. Management said disclosure controls were effective and prior material weaknesses in financial reporting controls were remediated by year-end; the auditor did not attest to internal controls, under the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Cash burn, actual cash runway, and whether management’s “into 2024” estimate remains supportable as trial and manufacturing costs rise.
- Final, audited clinical data for each ONA-XR study, including efficacy, patient numbers, biomarker findings, and liver-safety outcomes.
- Progress toward selecting a CLDN6xCD3 candidate and the timing, cost, and financing required for IND-enabling and clinical work.
- Potential dilution from outstanding warrants and equity-plan awards, and the terms and milestones of the Integral and Tyligand arrangements.
- Whether the remediated financial-control processes remain effective as the company grows and its public-company reporting obligations expand.